Skip to content

Medical emergency? What to do

AstraZeneca drug extends prostate cancer survival

3-RXPublished September 26, 20073 min read

Key points

  • Patients with advanced prostate cancer given AstraZeneca's experimental pill ZD4054 live around seven months longer than those on placebo, according to results of a clinical trial presented on Tuesday.
  • AstraZeneca said in July that ZD4054 demonstrated overall survival benefits and was being moved into final phase III studies.
  • Men with advanced prostate cancer are normally given hormonal therapies, which can be highly effective.
  • In the study of 312 pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer (HRPC), the median survival time for those on 10 milligrams of ZD4054 was 24.5 months, against 17.3 months for placebo.

Patients with advanced prostate cancer given AstraZeneca's experimental pill ZD4054 live around seven months longer than those on placebo, according to results of a clinical trial presented on Tuesday.

But the drug - which some analysts think could be a blockbuster - failed to show an improvement in progression-free survival, a measure of how long patients survive before their condition worsens.

AstraZeneca said in July that ZD4054 demonstrated overall survival benefits and was being moved into final phase III studies. The scale of the improvement was revealed at the European Cancer Conference in Barcelona.

The Anglo-Swedish firm hopes the new medicine, which could be filed for approval in 2009, will revive its fortunes in the fast-growing cancer treatment market.

Men with advanced prostate cancer are normally given hormonal therapies, which can be highly effective. But in most cases resistance develops - leaving Sanofi-Aventis's chemotherapy drug Taxotere, which improves survival by around 2.4 months, as the only option.

Nick James, professor of clinical oncology at the Institute for Cancer Studies in Birmingham, England, said the phase II trial results with the new once-daily pill were "promising".

In the study of 312 pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer (HRPC), the median survival time for those on 10 milligrams of ZD4054 was 24.5 months, against 17.3 months for placebo.

Those given a 15 mg dose of the drug lived 23.5 months.

However, the study failed to show a statistically significant difference in progression-free survival (PFS), which had been its primary endpoint.

"It is usual to use PFS as an endpoint in phase II studies; however, it can be difficult to measure accurately in patients with metastatic HRPC. Overall survival is an unambiguous endpoint and clearly an important outcome for patients," James said.

Deutsche Bank analyst Mark Purcell, who rates the stock a "buy", said the seven-month survival benefit compared very favourably with Taxotere. He raised his forecast for sales of the drug by 2012 to $460 million from $182 million previously.

"Assuming a $2,000 per month treatment cost and a 25 percent patient penetration rate, ZD4054 carries more than $1 billion sales potential," he said in a note.

Other industry analysts said ZD4054 still needed to prove itself decisively in phase III tests.

The field is littered with prostate cancer drugs that have not won approval, including a similar product called Xinlay from Abbott Laboratories, which was rejected by U.S. regulators in 2005 after it failed to delay disease progression.

ZD4054 works by blocking the action of a cell protein called endothelin A, which is believed to play a key role in prostate tumour growth.

AstraZeneca shares were 0.3 percent higher in a sharply lower London market by 1310 GMT.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Drug News

Drug shows early promise in treating seizures

A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure. The discovery…

5 min read

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.